MPR Weekly Dose Podcast #264 — Hep B Birth Dose Study; FDA Approves Treatments for Pancreatic, Ovarian Cancer; Priority Review for Narcolepsy Treatment

Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a pembrolizumab-based regimen for platinum-resistant ovarian cancer, and the granting of priority review to oveporexton for narcolepsy type 1.